Moffitt Cancer Center | Strategic Alliance Partners

September 11, 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, compares toxicity profiles of ibrutinib and acalabrutinib.

September 10, 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

September 07, 2018

Julio Chavez, MD, assistant member, Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of blinatumomab (Blincyto) in patients with acute lymphoblastic leukemia (ALL).

September 07, 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the changing landscape of acute myeloid leukemia (AML).

September 07, 2018

Rachid Baz, MD, discusses the ARROW, ELOQUENT-3, and OPTIMISMM studies and highlights others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

September 07, 2018

Bijal D. Shah, MD, discussed the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.

September 07, 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

September 06, 2018

Celeste Bello, MD, discusses the latest advances in the treatment of patients with follicular lymphoma.

September 05, 2018

Rachid Baz, MD, associate member, head of the Myeloma Section at Moffitt Cancer Center, discusses the potential use of selinexor (KPT-330) in patients with multiple myeloma.

August 31, 2018

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses novel agents in multiple myeloma.

August 31, 2018

Andrew T. Kuykendall, MD, assistant member, Moffitt Cancer Center, discusses the impact of ruxolitinib (Jakafi) in myeloproliferative neoplasms (MPNs).

August 31, 2018

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

April 30, 2018

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

April 25, 2018

Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.

April 24, 2018

Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.

April 23, 2018

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

March 30, 2018

Hung T. Khong, MD, medical oncologist, Moffitt Cancer Center, discusses the use of neoadjuvant endocrine therapy.

March 30, 2018

Heather S. Han, MD, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discusses the differences between CDK 4/6 inhibitors, and their efficacy as both single- and combination agents.

March 01, 2018

Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.

February 12, 2018

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the development of radiolabeled somatostatin analogs in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).